v3.26.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Financial Data for the Company’s Reportable Segment

The following table presents specific financial data for the Company’s reportable segment (in thousands):

 

(Dollar amounts in thousands)      
  

Three Months ended March 31,

 
(Dollar amounts in thousands)  2026   2025 
Operating expenses:          
Research & development expenses-clinical asset development  $262   $189 
Research & development expense – related parties   516    727 
General and administrative expenses – legal & professional fees   713    760 
General and administrative expenses – accounting & audit fees   709    544 
General and administrative expenses – salaries, payroll and SBC   543    693 
General and administrative expenses - other   913    703 
Total operating costs and expenses   3,656    3,616 
Operating loss   (3,656)   (3,616)
Other Expenses:          
Other expense   (290)   (969)
Loss on investment   (68)   - 
Interest Income   -    8 
Interest expense, net   (49)   (176)
Total other (expense) income, net   (407)   (1,137)
Net loss  $(4,063)  $(4,753)